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Intracranial atherosclerotic disease (ICAD) is the most common proximate mechanism of ischemic stroke worldwide. Approxi-
mately half of those aﬀected are Asians. For diagnosis of ICAD, intra-arterial angiography is the gold standard to identify extent of
stenosis. However, noninvasive techniques including transcranial ultrasound and MRA are now emerging as reliable modalities to
exclude moderate to severe (50%–99%) stenosis. Little is known about measures for primary prevention of the disease. In terms of
secondary prevention of stroke due to intracranial atherosclerotic stenosis, aspirin continues to be the preferred antiplatelet agent
although clopidogrel along with aspirin has shown promise in the acute phase. Among Asians, cilostazol has shown a favorable
eﬀect on symptomaticstenosisand isof beneﬁt intermsof fewer bleeds.Moreover, aggressive riskfactor management aloneand in
combination with dual antiplatelets been shown to be most eﬀective in this group of patients. Interventional trials on intracranial
atheroscleroticstenosishavesofaronlybeencarriedoutamongCaucasiansandhavenotyieldedconsistentresults.SincetheAsian
population is known to be preferentially eﬀected, focused trials need to be performed to establish treatment modalities that are
most eﬀective in this population.
1.Introduction
1.1.Epidemiology. Intracranialatheroscleroticstenosisofthe
major arteries (intracranial internal carotid artery, middle
cerebral artery, vertebral artery, and basilar artery) is the
most common proximate mechanism of ischemic stroke
worldwide [1]. It causes 30% to 50% of strokes in Asians [2]
and8%to10%ofstrokesinNorthAmericanCaucasians[3].
Intracranial atherosclerotic disease, ICAD, deﬁned as
atherosclerosis of the large arteries at the base of the brain,
preferentially aﬀects Asians, Hispanics, Far East Asians, and
Blacksascomparedtocarotidbifurcationdisease[3–6].Also,
about 20%–45% of non-Caucasians with large artery disease
have combined extracranial and intracranial lesions [7–10].
The prevalence of atherosclerotic stenosis by subtype and
race is further reported in Table 1.
2. PredisposingFactors for ICAD in
Susceptible Populations
2.1. Racial Associations. Sacco et al. [3] found no diﬀerence
between races in the proportion of patients with extracranial
atherosclerotic stroke, while intracranial atherosclerosis was
seen more frequently in African American and Hispanic sub-
jects than in Caucasian subjects. As per this study the greater
prevalence of Diabetes Mellitus in African American and
Hispanic subjects accounted for the increased frequency of
ICAD.
Waddy et al. [17]r e p o rtr a c i a ld i ﬀerences between blacks
and Caucasians with respect to intracranial stenosis. In this
study, risk of recurrence of stroke was higher in blacks and
risk factor proﬁles were also diﬀerent.
Among Chinese populations, ICAD-related strokes ac-
count for 33%–37% of all ischemic strokes and an even
higher prevalence is reported from Korea, Thailand, and Sin-
gapore [15, 16]. Hence, there is evidence of racial association
with incidence of ICAD.
2.2. Genetic Associations. Several studies suggest a positive
correlation between race and cerebrovascular disease [18,
19]. A study conducted on subjects of European ancestry
uncovered a genetic trait that increased their resistance to
atherosclerosis, though protection was conﬁned to large2 Stroke Research and Treatment
Table 1: Prevalence of intracranial atherosclerotic disease/extrac-
ranial atherosclerotic disease by race.
Race ICAD ECAD
South Asians [11, 12] 20%–54% 10%
East Asians [11] 7% 18%
US Whites [3, 13] 1%–24% 11%–33%
US Blacks [3, 13] 6%–22% 8%–15%
US Hispanics [3] 11% 9%
Chinese [14] 33%–50% 19%
Koreans [1, 15] 56.3%†–26.4% 12.2%
Singapore [1] 47.9% NR
Thailand [16] 47% 49%
†The authors used 30% stenosis as cutoﬀ.
ICAD: intracranial atherosclerotic disease, ECAD: extracranial atheroscle-
rotic disease.
intracranial vessels. It was speculated that stroke suppressor
genes activated antioxidants, such as Peroxidase 1, a compo-
nent of high density lipoprotein, which acted predominantly
in the intracranial arteries. Hence, polymorphic expression
of stroke suppressor genes in diﬀerent races accounts for
variable susceptibility to intracranial disease [20]. Secondary
prevention trials have so far failed to demonstrate beneﬁt of
antioxidants in reducing atherosclerotic complications [21,
22].However,sinceearlyatheroscleroticchangesbegininthe
cerebral arteries soon after teenage [23], future antioxidant
trials should intervene at very young age to determine a role
of antioxidants against the atherosclerotic process.
Most human genetic studies focus on polymorphic vari-
ants that promote stroke predisposing phenotypes or medi-
ators like targets in inﬂammatory pathways, modulators of
vascular tone and endothelial functions, lipid and homocys-
teine metabolisms, and components of haemostatic system.
Allelic association studies have so far yielded either conﬂict-
ing or only weak and modest connections [24–26].
Considering the racial diﬀerences in prevalence of ICAD,
and its predominance among the Asian population, there is
a need for genetic studies to be carried out in diﬀerent pop-
ulationsubsetstofurtherexplorethegenetictrends.Further-
more, research should explore our innate protective mech-
anisms against atherosclerosis and their expressions in
intracranial and systemic arteries among diﬀerent races.
2.3. Risk Factor Associations. The reasons for the disposition
towards more intracranial occlusive lesions in the Asian pop-
ulation remains unclear although various studies from the
past two decades have shown that coronary heart disease,
stroke, hypertension, and diabetes mellitus are associated
with more extensive cerebral atherosclerosis [4, 27]. Risk
factorsassociatedwithintracranialatherosclerosisarecertain
races (Hispanic Americans, blacks, and Asians), female
sex, young age, hypertension, smoking, diabetes, and lipid
disorders [3, 4, 6, 28, 29].
A WASID (warfarin versus aspirin in symptomatic
intracranial disease) substudy [17] has compared risk fac-
tors with respect to racial diﬀerences amongst blacks and
Caucasians.Theyfoundthatblackswithintracranialstenosis
were more likely to have hypertension, diabetes, high LDL,
and high total cholesterol. Other studies report that com-
pared to extracranial atherosclerosis, intracranial atheroscle-
rosis is not associated with typical risk factors for peripheral
and coronary atherosclerosis: male sex and hypercholes-
terolemia [3, 4].
Metabolic Syndrome, but not its isolated components,
hasbeenfoundtobeindependentlyassociatedwithintracra-
nial atherosclerosis, suggesting screening and treatment of
metabolic abnormalities as an important prevention strategy
[30].TheNorthernManhattanstrokestudy[31]alsoshowed
that the metabolic syndrome confers a greater risk of devel-
opment of intracranial atherosclerotic strokes compared to
extracranial atherothrombotic and non-atherothrombotic
strokes.
Another recent analysis [32] on WASID patients has
shown that severity of stenosis depends most strongly on
lipid disorder but also has an association with diabetes and
the metabolic syndrome. The study also highlights that
the location of intracranial stenosis depends on diﬀerent
vascular risk factors suggesting that the underlying patho-
physiology among diﬀerent intracranial vessels may be
diﬀerent.
2.4. Clinical and Radiological Presentation of Stroke. Patients
with intracranial atherosclerotic disease present with is-
chemic strokes in the territory of the aﬀected artery. The
mechanisms proposed in ischemia include artery-to-artery
embolism, local branch occlusion, hemodynamic compro-
miseresultingfromprogressivearterialnarrowing,oracom-
bination of these factors [33].
The radiological presentation of these strokes has been
described in several studies. These presentations include
cortically based infarctions [34], border zone infarctions [35,
36] and lacunes [37–39]. Multiple cortical and subcortical
infarcts have been reported in a study of patients with
MCA stenosis [33], and this has been linked to presence
of embolic signals on transcranial Doppler (TCD) exam
of these patients. This ﬁnding suggests artery-to-artery
embolism as the likely mechanism for this stroke subtype.
Infarctions in the territory of MCA perforators have also
been described in another magnetic resonance imaging-
(MRI-) based study [40] and the underlying mechanism
proposed is atherosclerotic branch occlusion.
Both internal and cortical border zone infarctions of the
MCA territory are reported in literature to result from ICAD
[41,42].Withprogressivenarrowingofthelargeartery,there
is a reduction in ﬂow, and since this happens gradually,
leptomeningeal collaterals form. When the compromise rea-
chesastagewhenthesecollateralsareinsuﬃcienttomaintain
perfusion to the terminal areas, infarctions develop in these
borderzone territories [43]. Multiple lesions in the unilateral
anterior circulation and small scattered lesions in one vas-
cular territory are also related to large-artery atherosclerosis
[33, 44, 45].
2.5. Natural Course and Clinical Prognosis. The natural
history of stenosis secondary to intracranial atherosclerosis
has been angiographically studied by Akins et al. [46]. Over
a follow-up period of 26.7 months, they reported an increaseStroke Research and Treatment 3
in the degree of stenosis in the MCA-ACA-PCA group,
whereas intracranial ICA stenoses remained stable. They
also reported a 14% regression in intracranial ICA stenosis
and a 28% regression in the MCA-ACA-PCA group. They
concluded that intracranial lesions are dynamic and may
progress or regress with time.
As t u d yb yK w o ne ta l .[ 47], evaluating the role of cilosta-
zol in ICAD, describes both progression and regression in
these lesions. In a more recent study [48] evaluating the role
of cilostazol and clopidogrel in intracranial atherosclerosis,
a total of 14% patients demonstrated lesion progression.
ICAD has also been evaluated in terms of development
of stroke in the territory of the diseased vessel. The risk
of future ischemic strokes depends on whether the vessel is
asymptomatic or symptomatic. This diﬀerence has been well
studied in the WASID trial [49]. Patients recruited in the
trial, though symptomatic, also had asymptomatic stenoses
in other arteries. When these patients were followed up, the
1-year risk of developing a stroke in the territory of these
asymptomatic vessels was 3.5% (CI 0.8%–9%). In contrast
to this, patients with ≥70% stenosis had a risk of 14% at one
year for a stroke in the same territory and 19% for stroke in
any vascular territory. Apart from severity of stenosis, recent
symptoms and female gender also predicted risk of stroke
recurrence in this study [50]. A similar risk rate of 14% was
reported from the GESICA (Groupe d’Etude des St´ enoses
Intra-Crˆ aniennes Ath´ eromateuses symptomatiques) study
[51].
A WASID substudy [52] has identiﬁed that the presence
of collaterals is a strong predictor of subsequent stroke in
case of moderate-to-severe stenosis, but milder stenoses are
more unstable and presence of collaterals in these predicts an
increased risk of subsequent stroke.
2.6.Diagnosis. Inpatientswithclinicalsuspicionofintracra-
nial steno-occlusive lesions, accurate assessment of intracra-
nial arteries is essential for optimal therapeutic decisions.
The options for imaging patients with intracranial steno-
sis include noninvasive techniques such as transcranial
Doppler or magnetic resonance angiography (MRA), such as
contrast-enhanced (CE) MRA and CE computerized tomog-
raphy CT.
Catheter cerebral angiography, though invasive, is con-
sidered to be the gold standard for diagnosis of ICAD. The
complication rates associated with the procedure performed
by trained neurointerventionists have gone down signiﬁ-
cantly. A recent review [53] of six-year data based on 363
diagnostic angiographies reports a low complication rate of
0.3% and an even lower risk of stroke (0.03%).
MRA is being proposed as a replacement for the gold
standard, intra-arterial angiography. 3D time-of-ﬂight
(TOF) MRA is currently the most commonly used pulse
sequence in the MR evaluation of intracranial arteries. It
detects clinically signiﬁcant stenotic lesions in intracranial
vessels. The other potential ﬁeld of application is to monitor
the response of a stenotic lesion to antistenosis medications
[47].
Both TOF MRA and CE MRA have shown [54]h i g h
accuracy for the detection of high-grade ICA stenosis and
occlusions. CE MRA has some edge over TOF MRA. How-
ever, for moderately severe stenosis, both had only poor
(TOF-MRA) to fair (CE MRA) sensitivity. Also, 3D TOF-
MRA can be restricted by factors such as susceptibility arti-
facts near the sphenoid sinus, limited scan range, limited
spatialresolution,andﬂowsignalintensitylossduetosatura-
tion or phase dispersion [55, 56]. The portion of intracranial
vessels near the skull base and especially the paracavernous
and supraclinoid segments of the internal carotid arteries
are areas of frequent over and underestimation of stenosis
due to the presence of dephasing artifacts. Some of these
limitations can be overcome by use of CE MRA which is not
ﬂow dependant.
When 3 Tesla MRI is used, the sensitivity of TOF-MRA
for >50% stenosis is reported to be 78%–85% with a positive
predictive value 75%–79%, and for complete occlusions, the
sensitivity and positive predictive values are in the range of
100% and 87%, respectively [57].
A recent paper by Arenillas [58] has highlighted a new
concept of intracranial plaque imaging using high resolution
(3T) 3D TOF-MRA. This gives the advantage of charac-
terization of plaque, detection of nonstenotic intracranial
atheroma, and detection of intraplaque hemorrhage. This
is yet to come into widespread clinical practice due to
nonavailability and limited clinical value. However, it is
interesting, because it characterizes lesser degrees of stenosis.
In a comparative study [59], the ability of helical CT
angiography (CTA) to help detect and quantify intracranial
stenosis and occlusion compared with DSA (digital subtrac-
tion angiography) and MRA was evaluated. CTA revealed
higher sensitivity than MRA for intracranial stenosis (98%
versus 70%, P<. 001) and occlusion (100% versus 87%,
P = .02).
Transcranial Doppler, TCD is another noninvasive and
easy to perform modality used for evaluation of ICAD.
The stroke outcomes and neuroimaging of intracranial
atherosclerosis (SONIA) trial [60] showed that both TCD
andMRAidentify50%to99%intracraniallargevesselsteno-
sis with a signiﬁcant negative predictive value. Therefore,
both canreliably exclude the presenceof intracranial stenosis
though abnormal ﬁndings would require a conﬁrmatory test
such as angiography to reliably identify stenosis.
Yet, another study [61] shows that advanced ultra-
sonographic techniques like power-ﬂow imaging and color
Doppler-assisted duplex imaging with and without contrast
haveabetteryieldfornear-occlusionandcompleteocclusion
detection.
Available noninvasive imaging modalities and their
sensitivity and speciﬁcity of detection with respect to degree
ofstenosisisenlistedinTable 2.Overall,noninvasiveimaging
modalities have a high negative predictive value in detecting
intracranial atherosclerosis. The gold standard for conﬁrma-
tion of the diagnosis remains intra-arterial angiography.
3. Treatment of Atherosclerotic
IntracranialStenosis
3.1. Medical Management. The medical management of int-
racranialatheroscleroticdiseasehasbeenevaluatedinseveral4 Stroke Research and Treatment
Table 2: Comparison of nonimaging modalities in the detection of intracranial stenosis.
Modality Degree of stenosis Sensitivity Speciﬁcity Limitations
Digital subtraction
angiography
Invasive test: Procedure risk rate: 0.3% for all
complications, 0.03% for stroke [56]
MRA (TOF) [54]f o r
ICA disease
50%–69% 37.9% 92.1%
Limited spatial resolution, ﬂow signal intensity loss as a
result of saturation or phase dispersion, susceptibility
artifacts near sphenoid sinus, and over- and
underestimation of stenosis due to dephasing artifacts
>70%–99% 91.2% 88.3%
ICA occlusion 94.5% 99.3%
MRA (TOF) 3T [57]
50%–99% stenosis 78%–85% 95%
Occlusion 100% 99%
MRA (CE) [54]
50%–69% 65.9% 93.5%
>70%–99% 94.6% 91.9%
ICA occlusion 99.4% 99.6%
CTA∗ [59]
Stenosis‡ 98% 99%
Occlusion 100% 100%
Transcranial Doppler
Ultrasound [62]
>50% stenosis or
occlusion
High level of technical and procedural skill is required
to obtain the best quality images. Reliable insonation of
the posterior circulation is particularly diﬃcult
For MCA stem (M1) 90%–99% 90%–99%
For intracranial
segment (V4) of
vertebral and basilar
artery
70%–80% 90%–99%
CDDI [61]
Atheromatous
pseudo-occlusion
Unenhanced† 70% 92% False negative rate 30%
Echo-enhanced PFI 83% 92% False negative rate 17%
Unenhanced 95% 92% False negative rate 5%
Echo-enhanced 94% 100% False negative rate 6%
CDDI: Color Doppler-assisted duplex imaging, PFI: power-ﬂow imaging.
∗Data are percentages using DSA as the reference standard.
‡North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria were used for stenosis calculations: [(Dn − Ds)/Dn] × 100, where Dn is
normal diameter and Ds is stenosed diameter. NASCET stenoses were grouped according to the following grading scale: normal (0%–9%), mild (10%–29%),
moderate (30%–69%), severe (70%–99%), or occluded (no ﬂow detected). Normal (0%–9%) and mild (10%–29%) stenosis were not considered diseased
vessel segments and were excluded from analysis.
†Ultrasound emission energy and gain cannot be increased high enough without the appearance of disturbing acoustic noise that diminishes the reliable
depiction of orthograde ﬂow signals.
trials over the past decade. There is no data on primary pre-
vention of strokes in patients with asymptomatic stenosis.
The eﬀectiveness of Aspirin in secondary prevention of
ischemic strokes is irrefutable. Since international stroke
trial—ISTandchineseacutestroketrial—CAST[63,64],itis
the standard of care. For intracranial atherosclerotic strokes,
it has never been tested in isolation, but extrapolating from
this data, the beneﬁt spans across all stroke subtypes.
For secondary prevention, anticoagulation with warfarin
was shown to be less safe and equal in eﬃcacy to aspirin in
the WASID (warfarin versus aspirin in symptomatic intra-
cranial disease) trial [49]. WASID was stopped early after
a mean followup of 1.8 years because of higher rates of death
and major hemorrhage in the warfarin group. The rates of
myocardialinfarctionorsuddendeathwerealsohigherinthe
warfarin group. The primary end point of ischemic stroke,
brain hemorrhage or vascular death, occurred in 22.1%
of patients in aspirin and 21.8% of those in the warfarin
group. Before WASID, it was thought that patients with
vertebrobasilar disease might beneﬁt from warfarin, but the
study failed to show a signiﬁcantly lower rate of primary end
point orstroke in the group onwarfarin[65],suggestingthat
there is no clear evidence for supremacy of warfarin over
aspirin for patients with vertebrobasilar stenosis either.
Eﬃcacy of other antiplatelet agents has been evaluated
in several other trials, and aspirin/extended release dipyri-
damole [66] is recommended over aspirin for secondary
prevention of all ischemic strokes. Clopidogrel [67] was also
shown to be superior to aspirin for composite vascular end
points. Therefore even though not subtype speciﬁc, there is
a role for these agents in ischemic strokes. Another more
recent study (prevention regimen for eﬀectivelyavoidingsec-
ond strokes—PRoFESS) has shown similar stroke recurrence
rates in patients with various underlying causes of stroke
and in a subset of patients with large artery atherosclerosis
when treated with clopidogrel alone versus a combination of
aspirin/extended release dipyridamole [68].
Therefore, as per the American Stroke Association rec-
ommendation [69], aspirin alone, aspirin/extended release
dipyridamole, and clopidogrel alone are all acceptableStroke Research and Treatment 5
options for secondary stroke prevention after a non-cardi-
oembolic ischemic stroke including large artery atheroscle-
rotic stroke.
Ar e c e n tt r i a l[ 70] investigating the role of combination
antiplatelet (aspirin+clopidogrel) in acute management of
stroke secondary to large artery atherosclerosis has shown
promise. The study demonstrated that early combination
therapy (within 7 days of symptom onset) was more eﬀective
than aspirin alone in reducing microembolic signals in
symptomatic arteries of these patients. Whether this trans-
lates into clinical beneﬁt is yet to be evaluated.
Cilostazol is a newer antiplatelet agent being investigated
for intracranial stenosis. It is a phosphodiesterase 3 inhibitor
that inhibits smooth muscle cell growth in vitro and has an
antiatherogenic and antiproliferative action in addition to
antiplatelet eﬀects. The ﬁrst study [47] evaluating cilostazol
in a randomized fashion came out in 2005. In this study,
during a 6-month follow-up period, there were no strokes in
cilostazol+aspirin or placebo+aspirin arm. However, pro-
gression of the intracranial stenosis was signiﬁcantly less in
the cilostazol group (6.7% versus 28.8%; P = .008).
This ﬁnding led to a multicenter study of cilosta-
zol+aspirin versus clopidogrel+aspirin in patients with sym-
ptomatic intracranial stenosis, the trial of cilostazol in symp-
tomatic intracranial arterial stenosis II (TOSS II) [48]. TOSS
II enrolled 456 acute ischemic stroke patients with symp-
tomaticintracranialarterialstenosis.After7monthsoftreat-
ment, follow-up MRA showed a slightly lower but signiﬁcant
rate of progression (9.90% versus 15.46%) and a higher
rate of regression (30.20% versus 23.67%) in symptomatic
stenosiswithcilostazolversusclopidogrelgroup,respectively.
More patients in the cilostazol group had new asymptomatic
ischemic lesions at the follow-up MRA than those receiving
clopidogrel (18.68% versus 12.04%), and in the territory
of the symptomatic intracranial stenosis (12.09% versus
8.90%), but this diﬀerence was not statistically signiﬁcant.
There was no statistically signiﬁcant diﬀerence in the
occurrence of clinical events by treatment group although
events tended to be more frequent in the cilostazol. Bleeding
complications were nonsigniﬁcantly higher with clopidogrel.
Therefore, cilostazol combination therapy had a favorable
eﬀect on the overall change in symptomatic intracranial
atherosclerotic stenosis, but in this study, it did not translate
into better clinical outcomes.
A pilot study [71] of Chinese patients with ischemic
strokes has compared aspirin to cilostazol in a randomized
fashion. There were fewer ischemic and hemorrhagic strokes
in the cilostazol group, suggesting that it might be safer and
more eﬀective compared to aspirin. Cilostazol stroke pre-
vention study 2—CSPS-2 [72] is a more recent randomized
trial that has shown that cilostazol is noninferior to and may
be superior to aspirin in prevention of recurrent stroke in
patients with noncardioembolic ischemic strokes. One third
of the patients in this trial had large vessel atherosclerosis.
Management of Risk Factors. WASID presented additional
data supporting aggressive risk-factor control in patients
with intracranial stenosis. In WASID, vascular risk factors
were managed by following national guidelines [48]. How-
ever, in many patients risk-factor control was not optimal,
andpatientswithpoorcontrolofriskfactorshadhigherrates
of recurrent vascular events [73, 74].
A WASID-substudy [74] demonstrated that elevated
blood pressure was associated with an increased risk of is-
chemic stroke and other major vascular events. Contrary to
the common practice of permissive hypertension in high-
grade stenosis, this study showed no increased risk with
maintaining blood pressures in the normal range. The
ﬁndings cannot be generalized to acute, unstable patients,
but the rest the guidelines for blood pressure control should
be followed.
Elevated LDL also conferred a high risk of subsequent
events in the WASID study [73]. Although the diﬀerence
failed to reach statistical signiﬁcance, there were fewer vas-
cular events in patients with LDL <70 compared to those
with levels ≥70. Based on this data and the SPARCL (stroke
prevention by aggressive reduction in cholesterol levels) trial
[75], the recommendation is for aggressive lipid lowering
with statin in patients with atherosclerotic ischemic stroke.
Another WASID substudy [76] has demonstrated that
metabolic syndrome is associated with intracranial ather-
osclerosis and confers a higher risk of major vascular events
in these patients. It is, therefore, an important additional
target for primary as well as secondary prevention of intra-
cranial atherosclerotic strokes.
In short, better control of risk factors that promote ath-
erosclerosis like diabetes, tobacco use, and particularly hyp-
ertension, dyslipidemia, and metabolic syndrome is war-
ranted in patients with intracranial atherosclerosis.
3.2. Endovascular Therapies. In earlier reports, intracranial
angioplasty had a high risk of complications, and the proce-
dure was abandoned [77]. Since then, several factors have led
to renewed attention in intracranial angioplasty and stent-
ing. These include advances in microcatheter and balloon
technology, high risk of recurrent stroke in patients with
intracranialstenosisdespitemedicalmanagementinWASID,
and success of endovascular treatments for coronary artery
disease [78].
3.3. Angioplasty. Data on angioplasty without stenting is
restricted to retrospective studies only. These studies report
a high technical success rate (with reduction of stenosis to
less than 50%). However, restenosis rates of up to 50% have
also been reported [79]. This study reports a periprocedural
death and stroke rate of 8.3% and an annual stroke risk of
4.4%. The procedure is associated with complications like
intimal dissection, thrombus formation, and vessel rupture
as well [80]. Long-term outcome after balloon angioplasty is
also yet to be prospectively studied.
3.4. Stenting. Stenting can be used as adjunct to balloon
angioplasty to prevent plaque recoiling and to cover a plaque
or an intimal ﬂap. It may also reduce the chances of vessel
dissection.6 Stroke Research and Treatment
The ﬁrst prospective trial on stenting was SSYLVIA
(stenting of symptomatic atherosclerotic lesions in the ver-
tebral or intracranial arteries) [81] performed in 2004. It was
a multicenter trial of use of bare metal stent for symptomatic
ICAD. It reported a technical success rate of 95%, 30-day
stroke risk of 6.6%, and a 1-year stroke risk of 8.5%. There
were no deaths reported. Although a restenosis rate of 35%
was seen, most of these were asymptomatic.
The next big trial on stenting used Wingspan [82]w h i c h
is a ﬂexible, self-expanding, microcatheter deployed stent.
This study was also a prospective multicenter trial on 45
patients refractory to medical therapy. Authors reported
atechnicalsuccessrateof97.7%,a30-daystrokeordeathrate
of 4.5%, and a 1-year stroke rate of 9.3%. Their restenosis
rates were better at 7.5% at 6 months and all were asymp-
tomatic. Long-term follow-up data is also now available for
Wingspan [83], and they report restenosis rates in the range
of 25%–32% although most is still asymptomatic.
Smaller case series report use of bare metal balloon-
mounted stents and drug eluting stents. The former are lim-
ited by their rigidity and the latter by nonavailability of long-
term safety data. Qureshi et al. [84] and Gupta et al. [85]
report use of drug coated stents in small number of patients
with good short term results in terms of restenosis. These
patients need to be on long-term antiplatelet therapy for at
least 12 months due to risk of subacute and late thrombosis.
Therefore, although technically safe and feasible, there is
a need for a long-term study.
Ac o m p a r a t i v es t u d y[ 86] of primary angioplasty and
stenting reveals no diﬀerence in terms of stroke free survival
at 2 years. Another systematic review [87], however, reports
a greater 1-year rate of stroke and death in the angioplasty
treated group compared to stent treated patients (20 versus
14%).
Comparison hasalsobeen done between aggressive med-
ical management and endovascular treatment with Wing-
span by Jarvis et al. [88]. They report a 13% rate of stroke
or death at 6 months with Wingspan and 16% with medical
management.
Based on this evidence, a prospective, randomized study,
stenting versus aggressive medical management for prevent-
ing recurrent stroke in intracranial stenosis (SAMMPRIS)
[89] was started in November 2008 to compare intensive
medical therapy alone with stenting plus intensive medical
therapy. The trial has very recently been halted with only
59% of the planned number of patients recruited. The major
reason for this early termination is an unacceptably high
complication rate in the stenting arm (14% patients had
a stroke or died in the 30-day period after stenting compared
to only 5.8% in the medical arm) [90]. One important
ﬁnding coming out from this trial is a much lower stroke
recurrence rate than that previously reported. Interestingly,
these patients were on combination antiplatelet therapy.
Hence, aggressive medical management may well be the way
forward for most patients.
3.5. Surgical Treatment. S i m i l a rt oc o r o n a r ya r t e r yb y p a s s
grafting, it is being speculated that a subgroup of patients
with intracranial stenosis may beneﬁt from External to
Internal carotid bypass. These patients are the ones who
have poor hemodynamic reserve. For assessment of hemo-
dynamic, several modalities are coming up including PET,
SPECT,TCD,CT,andMRperfusion.Withbetteruseofthese
modalities, it might be easier to identify patients who may
beneﬁtfromsuchabypassprocedure.Twotrialsarecurrently
underway to determine the eﬀectiveness of such a bypass
surgery, one in the US (carotid occlusion surgery study—
COSS)andtheotherinJapan(JapaneseEC-ICbypasstrial—
JET) [91, 92]. Before the ﬁnal verdict is out, the procedure
cannot be widely recommended (Table 3).
4. Summary of Therapeutic Options
At present, medical management with antiplatelets is the
mainstay of therapy for symptomatic intracranial stenosis.
Aspirin is the best studied, but in the acute phase, double
antiplatelet agents aspirin/extended release dipyridamole or
aspirin plus clopidogrel may be used. For long-term use,
combination of Aspirin and clopidogrel may not be as safe
and clopidogrel alone should be used. Cilostazol due to its
pleiotropic eﬀects has shown promise in Asians.
Aggressive risk factor control is recommended both for
symptomatic and asymptomatic disease. This includes agg-
ressive control of blood pressures and LDL cholesterol in
particular and of other atherogenic risk factors like diabetes
and tobacco use in general.
Endovascular management with angioplasty plus stent-
ing is emerging as a promising modality for high-grade
stenosis in patients with failure of medical management.
SAMMPRIS has been halted due to adverse eﬀects in the
interventionarm[90].Long-termoutcomesoftheprocedure
are yet unknown and restenosis is common, and hence, it
cannot be widely recommended.
SurgicaltreatmentwithEC-ICbypassisalsobeingevalu-
ated in two randomized trials. Pending results, this modality
also has limited application.
5. Conclusion
5.1. Known Facts about ICAD. Intracranial atherosclerotic
stenosismaybethemostcommoncauseofstrokeworldwide.
Asians are predominantly aﬀected, relative to other races.
Various genetic and environmental factors have been impli-
catedaspredisposingfactors.Althoughintra-arterialangiog-
raphy is the gold standard to identify extent of stenosis,
noninvasive techniques including TCD ultrasound and TOF
MRA have been established as reliable modalities to exclude
moderate-to-severe (50%–99%) stenosis. Also, CTA and PFI
can be used to correctly identify degree of severe stenosis.
In terms of secondary prevention of stroke due to int-
racranial atherosclerotic stenosis, aspirin continues to be the
preferred antiplatelet agent due to its eﬀectiveness compara-
tive to newer antiplatelet therapies. However, among Asians,
cilostazol has shown a favorable eﬀect on symptomatic sten-
osis and is of beneﬁt in terms of fewer bleeds. Combination
therapy has shown promise. Moreover, aggressive risk factor
management, that is, lowering blood pressure and LDL levels
lowers risk of vascular events. Endovascular therapy is stillStroke Research and Treatment 7
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investigational. Surgical treatment, that is, EC-IC bypass, has
failed to show any beneﬁt but may be helpful in selected
patients with poor hemodynamic reserve.
5.2. Unknown Facts about ICAD. Since Asians are at partic-
ular risk of stroke secondary to intracranial atherosclerotic
stenosis, studies to locate genetic markers responsible for
this racial predominance in lesion distribution would be of
interest. Implications of early detection and treatment of
asymptomatic intracranial stenosis need to be explored in
termsofbeneﬁtasastrokepreventionmodality.Noninvasive
diagnostic techniques that can reliably gauge extent of mild
and moderate intracranial stenosis have yet to be identiﬁed
and are needed. The role of antiplatelet agents other than
aspirin, in combination or as single therapy can still be
further investigated to advance current medical treatment
options. Endovascular therapy is still investigational and is
still associated with adverse eﬀects.
5.3. Future Directions. Conducted interventional trials on
intracranial atherosclerotic stenosis have so far only been
carried out among Caucasians. Since the Asian population is
known to be preferentially eﬀected, focused trials need to be
carried out to establish treatment modalities that are most
eﬀective in this population. Additionally, these may focus
on prevention, since intervention is expensive and requires
technical expertise in low- and middle-income countries
where these resources are scant. Screening for intracranial
stenosisneedstobefurtherexplored.Noninvasivediagnostic
modalities that can reliably identify all degrees of stenoses
are needed. For symptomatic patients, this will help in
management decisions, and for asymptomatic patients, they
may help explore the role of preventive therapy.
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